{"name":"Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives","slug":"groupe-d-etude-therapeutique-des-affections-inflammatoires-digestives","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"oncology","drugs":[{"name":"Start adalimumab in monotherapy","genericName":"Start adalimumab in monotherapy","slug":"start-adalimumab-in-monotherapy","indication":"Crohn's disease","status":"marketed"},{"name":"Azathioprine OR Mesalazine","genericName":"Azathioprine OR Mesalazine","slug":"azathioprine-or-mesalazine","indication":"Inflammatory bowel disease (Crohn's disease or ulcerative colitis)","status":"phase_3"},{"name":"CYCLOSPORINE VS INFLIXIMAB","genericName":"CYCLOSPORINE VS INFLIXIMAB","slug":"cyclosporine-vs-infliximab","indication":"Inflammatory bowel disease (Crohn's disease and ulcerative colitis)","status":"marketed"},{"name":"Mirikizumab - IV","genericName":"Mirikizumab - IV","slug":"mirikizumab-iv","indication":"Ulcerative colitis","status":"marketed"},{"name":"Mirikizumab - SC","genericName":"Mirikizumab - SC","slug":"mirikizumab-sc","indication":"Ulcerative colitis","status":"marketed"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Infliximab CT-P13","genericName":"Infliximab CT-P13","slug":"infliximab-ct-p13","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"Start adalimumab in monotherapy","genericName":"Start adalimumab in monotherapy","slug":"start-adalimumab-in-monotherapy","phase":"marketed","mechanism":"Adalimumab is a monoclonal antibody that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), reducing inflammatory signaling.","indications":["Crohn's disease","Ulcerative colitis","Rheumatoid arthritis","Ankylosing spondylitis","Psoriatic arthritis"],"catalyst":""},{"name":"Azathioprine OR Mesalazine","genericName":"Azathioprine OR Mesalazine","slug":"azathioprine-or-mesalazine","phase":"phase_3","mechanism":"This is a combination therapy study comparing azathioprine (an immunosuppressant) and mesalazine (an anti-inflammatory) for inflammatory bowel disease.","indications":["Inflammatory bowel disease (Crohn's disease or ulcerative colitis)","Induction and maintenance of remission in IBD"],"catalyst":""},{"name":"CYCLOSPORINE VS INFLIXIMAB","genericName":"CYCLOSPORINE VS INFLIXIMAB","slug":"cyclosporine-vs-infliximab","phase":"marketed","mechanism":"This is a comparative study evaluating cyclosporine (a calcineurin inhibitor) versus infliximab (a TNF-alpha inhibitor) for inflammatory bowel disease.","indications":["Inflammatory bowel disease (Crohn's disease and ulcerative colitis)","Severe steroid-refractory IBD"],"catalyst":""},{"name":"Infliximab CT-P13","genericName":"Infliximab CT-P13","slug":"infliximab-ct-p13","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Mirikizumab - IV","genericName":"Mirikizumab - IV","slug":"mirikizumab-iv","phase":"marketed","mechanism":"Mirikizumab is a monoclonal antibody that selectively inhibits IL-23 signaling by binding to the p19 subunit of IL-23, reducing inflammatory responses in the gut.","indications":["Ulcerative colitis","Crohn's disease"],"catalyst":""},{"name":"Mirikizumab - SC","genericName":"Mirikizumab - SC","slug":"mirikizumab-sc","phase":"marketed","mechanism":"Mirikizumab is a monoclonal antibody that selectively inhibits IL-23 signaling by binding to the p19 subunit of IL-23, reducing inflammatory responses in the gut.","indications":["Ulcerative colitis","Crohn's disease"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":6,"phaseCounts":{"marketed":5,"phase_3":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}